Relationship between serum RANTES levels and radiological progression in rheumatoid arthritis patients treated with methotrexate

Clinical and Experimental Rheumatology

Volumn 17, Issue 4, 1999, Pages 419-425

  Boiardi, L ^a   Macchioni, P ^a   Meliconi, R ^b,c   Pulsatelli, L ^c   Facchini, A ^b,c   Salvarani, C ^a  

^a S MARIA NUOVA HOSPITAL   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

Author keywords

Methotrexate; Rheumatoid arthritis; Serum chemokines

Indexed keywords

CHEMOKINE; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; METHOTREXATE; MONOCYTE CHEMOTACTIC PROTEIN 1;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BONE RADIOGRAPHY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; LEUKOCYTE ACTIVATION; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; STATISTICAL ANALYSIS;

ACUTE DISEASE; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CHEMOKINE CCL2; CHEMOKINES, CXC; CHEMOTACTIC FACTORS; FEMALE; FOLLOW-UP STUDIES; GROWTH INHIBITORS; GROWTH SUBSTANCES; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTERLEUKIN-8; MALE; METHOTREXATE; MIDDLE AGED; RANTES; SEVERITY OF ILLNESS INDEX;

EID: 0032865441     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. BAGGIOLINI M, DEWALD B, MOSER B: Human chemokines: An up-date. Annu Rev Immunol 1997; 15: 675-705.
2. BAGGIOLINI M: Chemokines and leukocyte traffic. Nature 1998; 392: 565-8.
3. SCHALL TJ, BACON KB: Chemokines, leukocyte trafficking and inflammation. Curr Opin Immunol 1994; 6: 865-73.
4. TAUB DD, OPPENHEIM JJ: Chemokines, inflammation and the immune system. Ther Immunol 1994; 1: 229-34.
5. KOCH AE, KUNKEL SL, BURROWS JC et al.: Synovial tissue macrophage as a source of chemotactic citokine IL-8. J Clin Invest 1991; 147: 2187-95.
6. KOCH AE, KUNKEL SL, SHAH MR et al.: Growth Related gene product alpha: A chemotactic cytokine for neutrophils in rheumatoid arthritis. J Immunol 1995; 155: 3660-6.
7. KOCH AE, KUNKEL SL, HARLOW LA et al.: Enhanced production of monocyte chemoattractant protein 1 in rheumatoid arhtritis. J Clin Investi 1992; 90: 772-9.
8. KOCH AE, KUNKEL SL, HARLOW LA et al.: Macrophage inflammatory proteins-1 alpha. A novel chemotactic cytokine for macrophage in rheumatoid arthritis. J Clin Invest 1994; 93: 921-8.
9. ROBINSON E, KEYSTONE EC, SCHALL TJ, GILLETT N, FISH EN: Chemokine expression in rheumatoid arthritis (RA): Evidence of RANTES and macrophage inflammatory protein (MIP)-1beta production by synovial T cells. Clin Exp Immunol 1995; 101: 398-407.
10. HOSAKA S, AKAHOSHI T, WADA C, KONDO H: Expression of the chemokine superfamily in rheumatoid arthritis. Clin Exp Immunol 1994; 97: 451-7.
11. WEINBLATT ME: Methotrexate. In KELLEY, HARRIS, RUDDY and SLEDGE (Eds.): Textbook of Rheumatology, 5th ed., W.B. Saunders Company, 1997; Chapter 49, pp. 771-86.
12. CRONSTEIN BN: Molecular therapeutics. Methotrexate and its mechanism of action. Arthritis Rheum 1996; 39: 1951-60.
13. PARMELY MJ, ZHOU W-W, EDWARDS CK III, BORCHERDING DR, SILVERSTEIN R, MORRISON DC: Adenosine and related carbocyclic nucleoside analogue selectively inhibit tumor necrosis factor alpha production and protect mice against endotoxin challenge. J Immunol 1993; 151: 389-96.
14. BOUMA MG, STAD RK, VAN DEN WILDENBERG FAJM, BUURMAN WA: Differential regulatory effect of adenosine on cytokine release by activated human monocytes. J Immunol 1994; 153: 4159-68.
15. SAJJADI FG, TAKABAYASHI K, FOSTER AC, DOMINGO RC, FIRESTEIN GS: Inhibition of TNF-alpha expression by adenosine: Role of A3 adenosine receptors. J Immunol 1996; 156: 3435-42.
16. LEMOINE O, STORDEURP, SCHANDENÉ L, et al.: Adenosine enhances interleukin-10 secretion by human monocytes. J Immunol 1996; 156: 4408-14.
17. KREMER JM, PETRILLO GF, LAWRENCE BA: Methotrexate induces significant changes in IL-1, IL-2, IL-6 and IL-8 but not lymphocyte markers in patients with rheumatoid arthritis. Arthritis Rheum 1993; 36: S77.
18. CRILLY A, MCINNES IV, MCDONALD AG, WATSON J, KAPEL HA, MADHOK R: Interleukin-6 and soluble interleukin-2 receptor levels in patients with rheumatoid arthritis treated with low-dose oral methotrexate. J Rheumatol 1995; 22: 224-6.
19. SPADARO A, TACCARI E, RICCIERI V, SENSI F, SILIS CAVALLIA, ZOPPINI A: Relationship of soluble interleukin-2 receptor and interleukin-6 with class specific rheumatoid factors during low-dose methotrexate treatment in rheumatoid arthritis. Rev Rheum 1997; 64: 99-104.
20. BARRERA P, HAAGSMA CJ, BOERBOOMS MTH, et al.: Effect of methotrexate alone or in combination with sulphalazine on the production and circulating concentration of cytokines and their antagonists. Longitudinal evaluation in patients with rheumatoid arthritis. Br J Rheumatol 1995; 34: 747-55.
21. BARRERA P, BOERBOOMS AMTH, JANSSEN EM et al.: Circulating soluble tumor necrosis factor receptors, inteleukin-2 receptors, tumor necrosis factor-alpha and interleukin-6 levels in rheumatoid arthritis. Longitudinal evaluation during methotrexate and azathioprine therapy. Arthritis Rheum 1993; 36: 1070-9.
22. SEITZ M, LOETSCHER P, DEWALD B, et al.: Interleukin-1 receptor antagonist, soluble tumor necrosis factor receptors, interleukin-1beta and interleukin-8 marker of remission in rheumatoid arthritis during treatment with methotrexate. J Rheumatol 1996; 23: 1512-6.
23. SEITZ M, LOETSCHER P, DEWALD B, et al.: Methotrexate action in rheumatoid arthritis stimulation of cytokine inhibitor and inhibition of chemokine production by peripheral blood mononuclear cells. Br J Rheumatol 1995; 34: 602-9.
24. ARNETT FC, EDWORTHY SM, BLOCH BA, et al.: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
25. FELSON DT, ANDERSON JJ, BOERS M, et al.: American College of Rheumathology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
26. BOIARDI L, SALVARANI C, MACCHIONI P et al.: Immunologic effect in patients with psoriatic arthritis treated with cyclosporin A. J Rheumatol 1992; 19: 1933-7.
27. LARSEN A, DALE K, ECK M, PAHLE J: Radiographic evaluation of rheumatoid arthritis by standard references films. J Hand Surg 1983; 8: 667-9.
28. PULSATELLI L, MELICONI R, BOIARDI L, MACCHIONI P, SALVARANI C, FACCHINI A: Elevated serum concentration of the chemokine RANTES in patients with polymyalgia rheumatica. Clin Exp Rheumatol 1998; 16: 263-8.
29. MACCHIONI P, BOIARDI L, MELICONI R, et al.: Serum chemokines in patients with psoriatic arthritis treated with cyclosporin A. J Rheumatol 1998; 25:320-5.
30. RATHANASWAMI P, HACHICHA M, SADICK M, SHALL TJ, MCCOLL S: Expression of the cytokine RANTES in human rheumatoid synovial fibroblasts. Differential regulation of RANTES and interleukin-8 genes by inflammatory cytokines. J Biol Chem 1993; 268: 5834-9.
31. OLIVA A, KINTER AL, VACCAREZZA M, et al.: Natural killer cells from human immunodeficency virus (HIV)-infected individuals are an important source of C-C chemokines and suppress HIV-1 entry and replication in vitro. J Clin Invest 1998; 102: 223-31.
32. BARNES DA, TSE J, KAUFHOLD M, et al.: Polyclonal antibody directed against human RANTES ameliorates disease in the Lewis rat adjuvant-induced arthritis model. J Clin Invesl 1998; 101: 2910-19.
33. QIN S, ROTTMAN JB, MYERS P, et al.: The chemokine receptor CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J Clin Invest 1998; 101: 746-54.
34. THOMAS R, CARROLL JG: Reduction of leukocyte and interleukin-1beta concentrations in the synovial fluid of rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum 1993; 36: 1244-52.
35. DOLHAIN RJEM, TAK PP, DIJKMANS BAC, DE KUIPER P, BREEDWELD FC, MILTENBURG AMM: Methotrexate reduces inflammatory cell numbers, expression of monokines and of adhesion molecules in synovial tissue of patients with rheumatoid arthritis. Br J Rheumatol 1998; 37: 502-8.
36. MATSUDA Y, YAMANAKA H, HIGAMI K, KASHIWAZAKI S: Time lag between active joint inflammation and radiological progression in patients with early rheumatoid arthritis. J Rheumatol 1998; 25: 427-32.